Total Payments
$924.59
2024 Payments
$145.40
Companies
13
Transactions
39
Medicare Patients
1,036
Medicare Billing
$81,537
Payment Breakdown by Category
Food & Beverage$858.60 (92.9%)
Education$65.99 (7.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $858.60 | 38 | 92.9% |
| Education | $65.99 | 1 | 7.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $263.11 | 8 | $0 (2024) |
| GlaxoSmithKline, LLC. | $147.54 | 7 | $0 (2024) |
| Novo Nordisk Inc | $106.28 | 4 | $0 (2024) |
| Horizon Therapeutics plc | $98.09 | 4 | $0 (2023) |
| Astellas Pharma US Inc | $65.99 | 1 | $0 (2023) |
| ABBVIE INC. | $63.95 | 4 | $0 (2024) |
| Lilly USA, LLC | $50.73 | 3 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $39.05 | 2 | $0 (2022) |
| Genentech USA, Inc. | $31.29 | 2 | $0 (2021) |
| Kowa Pharmaceuticals America, Inc. | $15.28 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $145.40 | 9 | ABBVIE INC. ($50.72) |
| 2023 | $490.75 | 16 | AstraZeneca Pharmaceuticals LP ($220.62) |
| 2022 | $106.80 | 6 | Bayer HealthCare Pharmaceuticals Inc. ($39.05) |
| 2021 | $181.64 | 8 | Novo Nordisk Inc ($71.99) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/01/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: RESPIRATORY | ||||||
| 07/29/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Diabetes | ||||||
| 06/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: NEUROSCIENCE | ||||||
| 06/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Endocrinology | ||||||
| 03/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: NEUROSCIENCE | ||||||
| 03/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/20/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: Medical Device | ||||||
| 02/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: Respiratory | ||||||
| 01/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $65.99 | General |
| 10/30/2023 | Kowa Pharmaceuticals America, Inc. | SEGLENTIS (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/20/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: RESPIRATORY | ||||||
| 08/22/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/27/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: RESPIRATORY | ||||||
| 06/15/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/13/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/13/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: KRYSTEXXA | ||||||
| 06/08/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY, SHINGRIX | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: RESPIRATORY | ||||||
| 06/02/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: RESPIRATORY | ||||||
| 05/01/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/26/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: KRYSTEXXA | ||||||
| 04/05/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: KRYSTEXXA | ||||||
| 03/14/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: KRYSTEXXA | ||||||
| 02/02/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug), BREZTRI | Food and Beverage | In-kind items and services | $50.23 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 331 | 477 | $75,880 | $26,764 |
| 2022 | 7 | 318 | 495 | $71,460 | $25,640 |
| 2021 | 9 | 318 | 476 | $64,178 | $24,507 |
| 2020 | 2 | 69 | 94 | $11,951 | $4,627 |
Total Patients
1,036
Total Services
1,542
Medicare Billing
$81,537
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 102 | 169 | $25,431 | $8,677 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 60 | 103 | $16,896 | $5,465 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 49 | $11,472 | $3,434 | 29.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 50 | 53 | $7,865 | $2,777 | 35.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 23 | 23 | $3,593 | $2,416 | 67.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 28 | $6,920 | $2,365 | 34.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 16 | 26 | $2,403 | $834.53 | 34.7% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 13 | 13 | $650.00 | $410.61 | 63.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 13 | 13 | $650.00 | $383.63 | 59.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 123 | 205 | $27,915 | $9,399 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 99 | $20,900 | $6,720 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 73 | $8,607 | $3,974 | 46.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 26 | 26 | $6,560 | $2,803 | 42.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 39 | 40 | $4,050 | $1,857 | 45.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 22 | 27 | $1,786 | $670.39 | 37.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 25 | $1,642 | $216.45 | 13.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 94 | 169 | $22,984 | $7,976 | 34.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 93 | $19,673 | $7,516 | 38.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 50 | 79 | $9,381 | $3,973 | 42.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 45 | 47 | $4,728 | $2,227 | 47.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 12 | 12 | $3,000 | $1,315 | 43.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 20 | 26 | $1,690 | $655.64 | 38.8% |
| 90756 | Vaccine for influenza derived from cell cultures for injection into muscle, quadrivalent, antibiotic free, 0.5ml dosage | Office | 2021 | 14 | 14 | $700.00 | $396.51 | 56.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 17 | 17 | $825.00 | $279.74 | 33.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 12 | 19 | $1,197 | $168.84 | 14.1% |
About Crystal Young, NP
Crystal Young, NP is a Family healthcare provider based in Vidor, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2019. The National Provider Identifier (NPI) number assigned to this provider is 1114566833.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Crystal Young, NP has received a total of $924.59 in payments from pharmaceutical and medical device companies, with $145.40 received in 2024. These payments were reported across 39 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($858.60).
As a Medicare-enrolled provider, Young has provided services to 1,036 Medicare beneficiaries, totaling 1,542 services with total Medicare billing of $81,537. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Vidor, TX
- Active Since 12/27/2019
- Last Updated 01/08/2024
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1114566833
Products in Payments
- FARXIGA (Drug) $234.96
- TRELEGY ELLIPTA (Drug) $147.54
- KRYSTEXXA (Biological) $98.09
- VRAYLAR (Drug) $63.95
- RYBELSUS (Drug) $57.91
- TRULICITY (Drug) $50.73
- Kerendia (Drug) $39.05
- Rybelsus (Drug) $34.29
- Xofluza (Drug) $31.29
- BREZTRI (Drug) $28.15
- SEGLENTIS (Drug) $15.28
- (AK6) Vest Therapy (Device) $14.82
- Dexcom G6 Transmitter (Medical Supply) $14.50
- Ozempic (Drug) $14.08
- Repatha (Biological) $13.96
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Vidor
Wendi Ames, Aprn, Fnp-C, APRN, FNP-C
Family — Payments: $2,141
Family $2,141
Kirsten Fournet, Fnp-C, FNP-C
Family — Payments: $884.63
Family $884.63
Terri Clark, Np, NP
Family — Payments: $452.84
Family $452.84
Talanna Ceara, Np, NP
Family — Payments: $87.69
Family $87.69
Heather Butler
Family
Family
Jenna Berg
Family
Family